Get the Stockscreener App
9.01
11.10%
0.90
Regenxbio Inc stock is traded at $9.01, with a volume of 1.36M.
It is up +11.10% in the last 24 hours and up +5.13% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$8.11
Open:
$8.15
24h Volume:
1.36M
Relative Volume:
1.60
Market Cap:
$455.13M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.7129
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
+2.15%
1M Performance:
+5.13%
6M Performance:
+23.93%
1Y Performance:
-22.73%
1-Day Range:
$8.07
$9.11
1-Week Range:
$7.8298
$9.11
52-Week Range:
$5.035
$13.48
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
9.01 | 439.98M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
DMD Plans Remain Central For Regenxbio Despite Hunter Syndrome FDA Approval Delay - insights.citeline.com
Delay hits Regenxbio BLA review - The Pharma Letter
Regenxbio says FDA extends review date for Hunter syndrome drug - MSN
FDA Extends Review Period for REGENXBIO Hunter Syndrome Treatment - BioPharm International
What recovery options are there for REGENXBIO Inc.July 2025 Intraday Action & Long-Term Investment Growth Plans - Newser
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year - Benzinga
FDA delays decision on Regenxbio gene therapy - statnews.com
Can trapped investors hope for a rebound in REGENXBIO Inc.Market Volume Summary & Stepwise Entry/Exit Trade Alerts - Newser
Regenxbio stock steady as FDA extends RGX-121 review timeline - Investing.com
Regenxbio Inc. shares rise 1.49% premarket after FDA review extension for RGX-121. - AInvest
Regenxbio stock holds steady as FDA extends review of Hunter syndrome gene therapy - Investing.com
FDA extends review of REGENXBIO’s Hunter syndrome therapy - Investing.com
FDA extends review of REGENXBIO’s Hunter syndrome therapy By Investing.com - Investing.com Nigeria
Regenxbio Says FDA Extends Review Timeline for RGX-121 - MarketScreener
Regenxbio's FDA Review Extension for RGX-121 and Its Implications for Gene Therapy Commercialization - AInvest
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II - Citizen Tribune
FDA Extends Review for RegenXBio’s RGX-121 Therapy - TipRanks
FDA delays decision on Regenxbio’s Hunter syndrome gene therapy by three months - Endpoints News
REGENXBIO Inc. Facing Inflection Point in Trend AnalysisJuly 2025 WrapUp & Verified High Yield Trade Plans - kangso.co.kr
Is a relief rally coming for REGENXBIO Inc. holdersMarket Sentiment Summary & Reliable Price Action Trade Plans - Newser
How REGENXBIO Inc. stock performs during market volatility2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Will breakout in REGENXBIO Inc. lead to full recovery2025 AllTime Highs & Verified Momentum Stock Alerts - Newser
What candlestick patterns are forming on REGENXBIO Inc.July 2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
Using data tools to time your REGENXBIO Inc. exitMarket Rally & Daily Stock Trend Watchlist - Newser
Can REGENXBIO Inc. hit a new high this month2025 Major Catalysts & Fast Gain Swing Trade Alerts - Newser
Trendline Breach Raises Concern for REGENXBIO Inc. Investors2025 Price Action Summary & Safe Capital Growth Tips - sundaytimes.kr
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet? - 富途牛牛
Technical analysis overview for REGENXBIO Inc. stock2025 Winners & Losers & Detailed Earnings Play Strategies - Newser
Detecting price anomalies in REGENXBIO Inc. with AIJuly 2025 Movers & Real-Time Volume Analysis - Newser
Can REGENXBIO Inc. rally from current levelsJuly 2025 Macro Moves & Advanced Technical Signal Analysis - Newser
REGENXBIO’s SWOT analysis: gene therapy pioneer’s stock faces pivotal year - Investing.com Canada
When is the best time to exit REGENXBIO Inc.Weekly Trade Recap & High Accuracy Investment Entry Signals - Newser
What makes REGENXBIO Inc. stock price move sharplyMarket Growth Review & Free Weekly Chart Analysis and Trade Guides - thegnnews.com
Are Options Traders Betting on a Big Move in Regenxbio Stock? - Yahoo Finance
What’s next for REGENXBIO Inc. stock priceFree Market Entry and Exit Point Tips - Newser
Investors Don't See Light At End Of REGENXBIO Inc.'s (NASDAQ:RGNX) Tunnel - simplywall.st
XTX Topco Ltd Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO (NASDAQ:RGNX) Cut to “Strong Sell” at Wall Street Zen - Defense World
Dystrophin Gene Therapy Market 2025 | $12B Growth, REGENXBIO & - openPR.com
Can REGENXBIO Inc. expand its profit marginsSafe Growth Small Cap Picks - thegnnews.com
Royal Bank Of Canada Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - Defense World
REGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan Capital - Defense World
Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX) - The Globe and Mail
These Analysts Just Made An Incredible Downgrade To Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Forecasts - Yahoo Finance
REGENXBIO Inc. recovery potential after sell offBuy Entry Confirmation Based on Technical Analysis - Newser
REGENXBIO (NASDAQ:RGNX) Stock Price Passes Below Fifty Day Moving Average on Disappointing Earnings - Defense World
REGENXBIO Reports Q2 2025 Financial Results and Progress - The Globe and Mail
Is REGENXBIO Inc. stock a buy or sellElite Portfolio Components - thegnnews.com
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026 - MSN
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Regenxbio Inc Stock (RGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mills Kenneth T. | Director |
May 12 '25 |
Sale |
7.91 |
20,602 |
163,046 |
475,103 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):